Isorhamnetin exerts anti-tumor activity in DEN + CCl 4 -induced HCC mice.
Sayanta SarkarAbhishek Kumar DasSemantee BhattacharyaRatan GachhuiParames C SilPublished in: Medical oncology (Northwood, London, England) (2023)
Regulating diverse cellular signaling pathways makes isorhamnetin a better anti-cancer chemotherapeutic candidate in HCC. Importantly, the anti-TNF-α properties of isorhamnetin could prove it a valuable therapeutic agent in sorafenib-resistant HCC patients. Additionally, anti-TGF-β properties of isorhamnetin could be utilized to reduce the EMT-inducing side effects of doxorubicin.
Keyphrases
- end stage renal disease
- newly diagnosed
- epithelial mesenchymal transition
- signaling pathway
- drug delivery
- rheumatoid arthritis
- chronic kidney disease
- high glucose
- prognostic factors
- liver injury
- adipose tissue
- type diabetes
- drug induced
- transforming growth factor
- metabolic syndrome
- pi k akt
- insulin resistance
- endothelial cells
- high fat diet induced
- skeletal muscle
- induced apoptosis
- endoplasmic reticulum stress